Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune response in mouse model systems

Bogyo, Dennis; Ehrke, M. Jane; Mihich, Enrico

doi:10.1016/0006-2952(82)90033-8

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells were washed, resuspended in RPMI-1640 medium with HEPES, and X-irradiated on ice in a 35 x 10-mm tissue-culture dish for a total of 4200 rad, at a rate of 200 rad/min and 10 cm target distance. 51Cr-labeled tumor cells used for targets in a 4-h lymphocytemediated cytotoxicity assay were prepared as previously described [3][4][5]. For in vivo allogeneic challenge 3 x 107 P815 mastocytoma cells were implanted i.p.…”

Section: Cb Treatmentmentioning

confidence: 99%

Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2

Bogyo

Fondy

Finster

et al. 1991

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Cytochalasin B (CB), administered i.p. to C57B1/6 mice in a single dose as a suspension in carboxymethylcellulose 2%/Tween 20 1%, inhibits in a dose-dependent and time-dependent manner the ability of spleen cells to respond to allogeneic P815 mastocytoma tumor cells in vitro. Spleen cells from CB-treated animals sensitized to X-irradiated P815 cells in 4-day cultures at a 50:1 responder:stimulator ratio and tested for specific cytotoxicity against 51Cr-labelled P815 target cells showed strong inhibition 3 h after CB treatment at a dose of 50 mg/kg. A dose of 25 mg/kg showed measureable but not statistically significant inhibition at 3 h, whereas 10 mg/kg produced only slight inhibition, and 5 mg/kg and 2 mg/kg were noninhibitory. None of the doses produced significant suppression 19 h or 72 h after CB treatment. Addition to the sensitization cultures of human recombinant interleukin-2 (rhIL-2) at 350 BRMP units/ml completely restored tumor lytic capacity. C57B1/1 mice treated with CB 50 mg/kg, i.p. and challenged i.p. with 3 x 10(7) allogeneic P815 mastocytoma cells showed a brief, time-dependent, statistically significant abrogation of allogeneic responsiveness consistent with transient reversible immunosuppression within 3-12 h following CB treatment. No such inhibition of host allogeneic responsiveness in vivo was observed when CB was administered 24 h prior to, simultaneously with, or 1, 2, or 4 days after tumor challenge. Thus CB at the highest tolerated i.p. dose in vivo causes only a transient inhibition of anti-allo-responsiveness measured in culture, and rhIL-2 used in vitro restores lytic capacity. The anti-allo effect of CB is also seen to be transient directly in vivo since allogeneic tumor outgrowth is permitted for only a brief period following administration of CB. These results indicate that the use of CB in vivo in anti-tumor chemotherapy protocols will not be complicated by profound or prolonged immunosuppressive effects.

show abstract

Section: Cb Treatmentmentioning

confidence: 99%